TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Del Bianco, Paola, Stagni, Camilla, Giunco, Silvia, Fabozzi, Alessio, Elefanti, Lisa, Pellegrini, Stefania, Vecchiato, Antonella, Pigozzo, Jacopo, Zamuner, Carolina, De Rossi, Anita, De Nicolo, Arcangela, Menin, Chiara
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://ncbi.nlm.nih.gov/pubmed/32290374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040946
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados